Abstract
Proof-of-concept study of evaluation of metabolic effect of novel oral spray insulin (Oralin) formulation at breakfast time in subjects with type 2 diabetes on multiple daily injections. This was an open-label, crossover, randomized study in (n = 23) subjects with type 2 diabetes on multiple daily injections. Subjects received each treatment, in random order, 3 to 7 days apart-a daily dose of SC injection (0.1 u/kg) on one occasion and Oralin spray (100 u) at time 0 min on another occasion. Subjects were given a standard breakfast containing 360 cal (Sustacal liquid meal) 10 min after the dose. Blood samples were taken at regular intervals to measure glucose, insulin, and C-peptide. The 30- and 60-min postprandial glucose levels were significantly lowered with Oralin versus that with the injection treatment (146 +/- 5 mg/dL Oralin vs 184 +/- 7 mg/dL injection at 30 min and 192 +/- 6 mg/dL Oralin vs 236 +/- 9 mg/dL injection, p < 0.003 at 60 min). The rise in serum insulin levels was significantly higher (Cmax = 98 +/- 6 uU/mL for Oralin at 30 min vs 65 +/- 3 uU/ml injection, p < 0.001). The reduction in C-peptide was greater in Oralin during the first 60 min (1.38 +/- 0.21 ng/mL Oralin vs 1.75 +/- 0.38 ng/mL injection, p < 0.00...Continue Reading
References
Aug 1, 1992·Diabetic Medicine : a Journal of the British Diabetic Association·H J GjessingO Pedersen
Apr 9, 1988·British Medical Journal·R Taylor
Feb 1, 1988·Diabetes Care·E S Horton
Jun 30, 1984·British Medical Journal·I Peacock, R B Tattersall
Dec 1, 1996·Diabetologia·K I BirkelandS Vaaler
May 19, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·D R MatthewsR C Turner
Jun 8, 1999·JAMA : the Journal of the American Medical Association·R C TurnerR R Holman
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
Jan 26, 2002·Journal of Clinical Pharmacology·Linda A JaberRichard R Slaughter
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jun 29, 2002·BMJ : British Medical Journal·Peter H Winocour
Citations
Jun 1, 2005·Archives of Medical Research·Francisco J Gómez-Pérez, Juan A Rull
Aug 21, 2007·Diabetes Technology & Therapeutics·Jaime Guevara-AguirreArlan L Rosenbloom
Nov 6, 2009·Diabetes, Obesity & Metabolism·Paolo PozzilliChristopher G Parkin
Dec 1, 2010·Diabetes, Obesity & Metabolism·A PalermoP Pozzilli
Aug 14, 2008·Clinical Pharmacokinetics·Paris Roach
Dec 19, 2013·International Journal of Endocrinology and Metabolism·Carlo Maria RotellaEdoardo Mannucci
Nov 2, 2006·Expert Opinion on Drug Delivery·Claudio GonzálezSilvina Santoro
Apr 21, 2012·Expert Opinion on Biological Therapy·Andrea PalermoPaolo Pozzilli
Nov 22, 2005·Expert Opinion on Drug Delivery·Marco van de WeertSven Frokjaer
Jun 25, 2015·Journal of Endocrinological Investigation·V AkbariS A Mostafavi
Apr 15, 2008·Endocrinology and Metabolism Clinics of North America·Lutz Heinemann
Dec 5, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Christiane DamgéNathalie Ubrich
Aug 23, 2005·Diabetes/metabolism Research and Reviews
Jun 17, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nicholas A Peppas, Nikhil J Kavimandan
Aug 4, 2015·Canadian Journal of Diabetes·Vincent C Woo
Sep 29, 2009·Atencion primaria·Zaida Herrador Ortiz, Aurora Llanos Méndez
Jul 1, 2005·Metabolism: Clinical and Experimental·Paolo PozzilliPankaj Modi
Feb 11, 2010·Journal of Diabetes Science and Technology·Lutz Heinemann, Yves Jacques
Jul 28, 2019·Minerva endocrinologica·Subhankar ChatterjeeJames H O'keefe